| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 25.6 | 14.5 |
| Profit before tax | -33.8 | -21.6 |
| Net income | -33.8 | -21.7 |
| EPS (diluted, $ a share) | $-0.32 | $-0.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +76.6% |
|---|---|
| Operating margin | -138.8% |
10-Q filed with the SEC, NASDAQ: PSNL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Personalis, Inc.: key numbers
- Share price
- $14.80Close, Nov 16
- Market cap
- $1.6B
- Shares outstanding
- 108.4MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Personalis, Inc.
All →Personalis Earnings Call: Key Takeaways
Personalis presented interim Victory study data for NeXT Personal, demonstrating 96% pre-surgical sensitivity and 100% detection of colorectal cancer recurrences with significant lead-time advantages.
Personalis CEO Christopher M. Hall Sells $462K of Stock
Christopher M. Hall, CEO, sold 29,112 shares of Personalis, Inc. at $15.87 a share, worth $462K in total on Nov 3, 2026. Shares held after the trade: 199,415 (-12.7%).
- Value
- $462K
- Shares
- 29,112
- Price
- $15.87
- Role
- CEO
- Holding change
- -12.7%
- Trade date
- Nov 3, 2026
Personalis Financial Results
Personalis reported Q3 2026 total revenue of $25.6 million, a significant increase from $14.5 million in the prior year, driven by growth in clinical test volume and population sequencing. The company ended the quarter with $190.6 million in cash and noted its pending merger with Tempus AI. Due to the pending acquisition, the company is no longer providing forward-looking financial guidance.
“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners.”
Chris Hall, Chief Executive Officer of Personalis
Personalis M&A Deal with Tempus AI, Inc.
Personalis announced the expiration of the Hart-Scott-Rodino (HSR) Act waiting period regarding its pending acquisition by Tempus AI, Inc. The expiration of the antitrust waiting period satisfies a key closing condition for the merger, which was originally announced on July 20, 2026. The transaction remains subject to approval by Personalis stockholders and other customary closing conditions.
- Counterparty
- Tempus AI, Inc.